Prompt follow-up

Breast cancerHR-positive, HER2-negative breast cancer

“HR-positive, HER2-negative” means the cancer cells usually have receptors for estrogen and/or progesterone, and do not have high levels of HER2 protein. Endocrine (anti-hormone) therapy is often part of care when appropriate, along with other treatments that depend on stage, risk, and your health.

This page is for education only. It does not replace a visit with a qualified clinician. Your care team’s advice for you may differ from what you read here.

Preview — not yet published

This page is in editorial and medical review. Content below is a scaffold — treat it as a preview, not guidance.

Orientation

What to do next

A simple timeline many people find useful — your team’s pace may be faster or slower.

  1. Today

    Confirm you know your exact ER, PR, and HER2 status on the pathology report, and what is still pending.

  2. This week

    Your team may order or review multigene risk tests in some early invasive cases, and will outline surgery, radiation, and/or systemic therapy based on stage and other factors.

  3. Over the next few weeks

    If endocrine therapy is recommended, you will talk about duration, side effects, and (when relevant) ovarian suppression or other add-on plans.

Decisions ahead

Results that often matter for next steps

  • ER and PR

    Usually positive; reported as a percentage and/or “positive”/“negative” by lab

    Hormone receptor status helps your team think about endocrine therapy, which is often a backbone of treatment for HR-positive disease when the plan includes systemic treatment.

    Ask: What are my exact ER/PR results, and how was HER2 testing done?

  • HER2

    Negative in this category (by approved testing)

    HER2-negative means anti-HER2 drugs are not used for HER2-driven treatment the way they are in HER2-positive disease.

    Ask: Is my HER2 result by immunohistochemistry, FISH, or both, and is it final?

  • Stage and nodes

    Tumor size, nodal status, and metastatic workup when used

    Stage and whether lymph nodes are involved are major drivers of which local and systemic options are standard.

    Ask: What stage and nodal status am I, and is there anything about my case that is borderline for chemotherapy?

  • Multigene test (in some cases)

    Assay results when ordered for early invasive HR+ disease

    In select situations, a tumor test may help discuss chemotherapy benefit. It is not used in every person or every age group.

    Ask: Is a multigene assay recommended for me, and when will I have results?

Treatment overview

Treatment by situation — not personal advice

Your care team tailors a plan to your specific stage, other health conditions, and preferences.

  • Early invasive HR+, HER2-

    Common options
    Surgery (lumpectomy or mastectomy) with radiation when used; endocrine therapy for many people; some people also receive chemotherapy depending on node status, size, grade, and tumor biology.
    Why this may come up
    The goal is often to remove the cancer, reduce the risk of it returning, and for many patients to use endocrine therapy for years when appropriate for invasive disease.
    Questions to ask
    What is the benefit and duration of endocrine therapy for me? Is chemotherapy on the table, and on what data?

  • Higher-risk or node-positive HR+, HER2-

    Common options
    Chemotherapy, ovarian suppression in some premenopausal patients, targeted add-ons in selected situations, radiation, and endocrine therapy may all be discussed depending on the details.
    Why this may come up
    Node status, tumor size, grade, age, menopausal status, and selected test results can change how much systemic treatment is considered.
    Questions to ask
    Which features make my case lower or higher risk, and which parts of the plan are meant to lower recurrence risk?

  • Metastatic HR+, HER2-

    Common options
    Endocrine therapy, targeted agents when appropriate, chemotherapy when needed, and other approaches depending on where the cancer is and what has been tried. Clinical trials may be options.
    Why this may come up
    Treatment choices for metastatic disease often follow lines of therapy and response, and may change as new information appears.
    Questions to ask
    What are our goals of treatment, how will we measure response, and when would we plan a new line or a trial discussion?

Research

Clinical trials and when to ask (HR+, HER2-)

Your doctor might mention a trial in early disease when a study fits your stage and tumor features, in metastatic disease as new lines of therapy are needed, or when a study is testing a new endocrine, targeted, or chemo approach that matches your situation. Trials have eligibility rules and informed consent; ask what standard options are available outside the study.

When to seek care

Emergency, prompt, and routine

Call 911 or seek emergency care if

  • Sudden shortness of breath, chest pain, fainting, or new confusion (could be many causes — get urgent care as directed)
  • Thoughts of self-harm — get immediate help; in the U.S., call or text 988

Call your care team promptly if

  • A new or rapidly enlarging mass in the breast or new bone pain in the setting of known cancer — call your team the same day
  • Fever, rapid breast redness, or new neurologic symptoms during treatment

Bring this up at your next visit if

  • Duration of endocrine therapy and options if side effects are intolerable
  • Menopause, bone health, and other long-term health during treatment
  • Second opinion before major treatment decisions, if you want one

For your next visit

Questions to ask your care team

  • Is my disease invasive or in situ, and is my HER2 result clearly negative by our lab’s standards?

  • What is my Ki-67, grade, and stage, and how do they change my plan?

  • If you recommend a multigene test, which one and when will I get results?

  • For how many years is endocrine therapy usually planned, and can we change drugs if I struggle?

  • Is there a clinical trial I should know about for my current stage and treatment line?

Review, sources, and disclaimer

How this page was reviewed

Medical review

Pending medical review. This page will list the reviewing clinician and review date before publication.

Content version 0.1

This page is educational, not medical advice. Talk with your care team about decisions that apply to you. If something feels urgent, contact your doctor — or, for emergencies, call your local emergency number.